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Oncosomes are tumor-derived microvesicles that
transmit signaling complexes between cell and tissue
compartments. Herein, we show that amoeboid tu-
mor cells export large (1- to 10-m diameter) vesicles,
derived from bulky cellular protrusions, that contain
metalloproteinases, RNA, caveolin-1, and the GTPase
ADP-ribosylation factor 6, and are biologically activetoward tumor cells, endothelial cells, and fibroblasts.
We describe methods by which large oncosomes can
be selectively sorted by flow cytometry and analyzed
independently of vesicles <1 m. Structures resem-
bling large oncosomes were identified in the circulation
of different mouse models of prostate cancer, and their
abundance correlated with tumor progression. Similar
large vesicles were also identified in human tumor tis-
sues, but they were not detected in the benign compart-
ment. They were more abundant in metastases. Our
results suggest that tumor microvesicles substantially
larger than exosome-sized particles can be visualized
and quantified in tissues and in the circulation, and
isolated and characterized using clinically adaptable
methods. These findings also suggest a mechanism by
which migrating tumor cells condition the tumor mi-
croenvironment and distant sites, thereby potentiating
advanced disease. (Am J Pathol 2012, 181:1573–1584;
http://dx.doi.org/10.1016/j.ajpath.2012.07.030)
Prostate cancer is the second leading cause of cancer-
related death in men in Western countries.1 Understand-
ing the biological aspects of progression to advanced,
untreatable prostate cancer and identifying reliable mark-
ers to assess disease course before and after therapy
remain major clinical challenges.
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size, tumor cells undergo a broad range of physical
and functional alterations, including cytoskeletal rear-
rangements and remodeling of the extracellular matrix
(ECM).2,3 Motile tumor cells assume several pheno-
types, including a mesenchymal mode, in which the
cells are elongated and fibroblast-like, and a distinct
amoeboid mode, with less adherent properties and
extensive membrane deformation.4,5 Amoeboid move-
ment through tissue spaces is characteristically rapid
and only minimally dependent on repetitive cycles of
membrane attachment and retraction to ECM.6,7
Amoeboid behavior is less understood in molecular
terms than mesenchymal motility; however, evidence
indicates that this migration mode is driven by Rho
GTPase-mediated actomyosin contractility.4,8,9 A re-
cent study from our group demonstrates that amoeboid
behavior can be induced by microtubule instability
caused by loss of the formin DIAPH3.10 Silencing of
DIAPH3 in prostate cancer cells and other tumor cell
backgrounds results in an abrupt transition to amoe-
boid behavior, characterized by formation and retrac-
tion of bulky membrane protrusions, as well as in-
creased motility, invasiveness, and metastatic
potential.10 We have also shown that prostate cancer
cells exhibiting amoeboid behavior release large (ap-
proximately 1- to 10-m diameter) membrane vesicles
into the medium from pinched membrane blebs.10,11
Notably, as demonstrated for the first time, to our
knowledge, in the current study, these structures are
large enough to be observed by light microscopy and
quantified by several methods potentially applicable to
clinical practice.
The term oncosome has been used to describe a
category of tumor-derived microvesicle (TMV) that can
propagate oncogenic information, including transfer of
signal transduction complexes, across tissue
spaces.12,13 Oncosomes identified in patients with
glioblastoma contained a hyperactive, mutated form of
epidermal growth factor receptor, which triggered ac-
tivation of downstream signaling pathways, such as
mitogen-activated protein kinase and AKT, in cells that
absorbed them.12 Such a horizontal transfer mecha-
nism can potentially deliver transforming signals of
many kinds throughout tissues and even to distant
sites.12 Most TMVs described in the literature are in the
approximately 80- to 500-nm-diameter range.14–16 Be-
cause membrane blebbing can produce a type of mi-
crovesicle large enough to be detected by methods
other than electron microscopy or biochemical isola-
tion, the question we address herein is whether such a
large tumor-derived vesicle can be observed and
quantified in situ in tumor tissues or in the circulation.
The Ras-like small GTP-binding protein ADP-ribosyla-
tion factor 6 (ARF6) was recently identified as a regu-
lator of actomyosin-based abscission of protease-
loaded vesicles from the plasma membrane of invasive
tumor cell lines.17 This mechanism results in secretion
of relatively large, ARF6-enriched vesicles from bleb-
bing cells,17 suggesting the possibility that large on-cosomes might be detected in vivo using antibodies to
ARF6 or other informative target proteins.
In the present study, we used a series of prostate
cancer models to test the hypothesis that large TMVs,
termed large oncosomes herein, can be identified and
quantified in plasma and tumor tissue. Our findings show
that such structures may be a common feature of aggres-
sive prostate cancer, including metastatic cancer in hu-
mans and mice; their evaluation can potentially provide
information on disease aggressiveness; and their pres-
ence in the microenvironment could be functionally in-
volved in metastatic dissemination and lethal biological
behavior of human tumors.
Materials and Methods
Cell Culture
LNCaP, DU145, PC3, and WPMY-1 were from ATCC.11,18,19
The LNCaP/LacZ and LNCaP/MyrAkt1 lines were de-
scribed.18 For the generation of LNCaP/Vo and LNCaP/
caveolin-1 (Cav-1), parental LNCaP cells were plated at
70% to 80% confluence and transfected using Lipo-
fectamine 2000 Tranfection Reagent (Invitrogen, Carls-
bad, CA). Stable populations were isolated after selection
with gentamicin G418, 0.5 mg/mL. The LNCaP cells were
cultured in RPMI 1640 medium supplemented with 10%
fetal bovine serum (Valley Biomedical, Winchester, VA), 2
mmol/L L-glutamine, 100 U/mL penicillin, and 100 g/mL
streptomycin (all from Invitrogen). The DU145 and PC3
cells were cultured in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% and 5% (WPMY-1) fetal
bovine serum, 2 mmol/L L-glutamine, 100 U/mL penicillin,
and 100 g/mL streptomycin.
DNA and RNA Extraction
Total nucleic acid was isolated by the TRIzol (Invitro-
gen) extraction method, and concentration was deter-
mined by using the NanoDrop 2000c spectrophotom-
eter (ThermoFisher Scientific, Inc., Waltham, MA). RNA
and DNA were fractionated by gel electrophoresis on a
2% agarose gel (Invitrogen), and nucleic acid purity
was evaluated by RNase A (Invitrogen) and DNase 1
(Sigma, St. Louis, MO) digestion. Nucleic acid (100 ng)
from vesicles obtained from 2  107 LNCaP/MyrAkt1
cells was suspended in 15 L of buffer for gel electro-
phoresis.
Immunoblot Analysis
Cells and purified vesicles were lysed and analyzed by
SDS-PAGE and Western blot analysis with the following
antibodies: rabbit polyclonal Cav-1 (N-20) (Santa Cruz
Biotechnology, Santa Cruz, CA); HA.11 monoclonal an-
tibody (mAb), clone 16B12 (Covance, Princeton, NJ);
Akt1 and p-Akt1 (S473), clone D9E (Cell Signaling,
Danvers, MA), at a dilution of 1:1000; and -actin mAb,
clone AC-15 (Sigma), at a dilution of 1:5000. The ARF6
antibody was a generous gift from Dr. Victor Hsu,
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tein, 15 g per lane, was loaded for Western blot
analysis.
Immunofluorescence Microscopy
Cells were incubated on ice with fluorescein isothiocya-
nate (FITC)–conjugated cholera toxin B (CTxB) subunit
(Sigma) or Alexa 594–conjugated CTxB (Invitrogen) and
analyzed as previously described.19 For selected exper-
iments, LNCaP/MyrAkt1 cells were fixed in 4% parafor-
maldehyde, stained with FITC-conjugated HA (MyrAkt1)
tag (Santa Cruz Biotechnology), and imaged using an
Axioplan 2 microscope (Zeiss, Oberkochen, Germany).19
Animal Models and Tumor Xenografts
All experiments were performed in compliance with the
guidelines of the Institutional Animal Care and Use Com-
mittee, Children’s Hospital Boston (Boston). We estab-
lished s.c. xenografts, injecting 2  106 LNCaP/LacZ or
LNCaP/MyrAkt1 cells into the flanks of 8 and 16 mice with
severe combined immunodeficiency, respectively. Tumor
growth was monitored three times per week from the
detection of the first palpable tumors, and the mice were
sacrificed before reaching the maximum tumor burden of
2000 cm3 at all four sites (6 weeks after implantation).
At necropsy, tumors were removed, weighed, fixed in
10% buffered formalin, and embedded in paraffin for
histological analysis. The colonies of transgenic mice
with autochthonous prostate tumors (TRAMP) and age-
matched wild-type mice were maintained in a
C57BL6/J background and genotyped as previously
described.21,22 In some experiments, TRAMP mice
from an F1 C57BL6/J  FVB/N cross were used.
PtenPbKO/Trp53PbKO and PtenPbKO/KRAS mice were
maintained as previously described.21
Oncosome Isolation
Oncosomes were purified from conditioned medium or
from 500 L of platelet-poor plasma, as previously de-
scribed.11 Briefly, cells and debris were eliminated by
centrifugation at 2800  g for 10 minutes. The superna-
tant was centrifuged at 100,000  g for 80 minutes.
Purified oncosomes were washed in PBS, stained with
the indicated antibodies, fixed and permeabilized in eth-
anol, then analyzed by fluorescence-activated cell sort-
ing (FACS) and sorted using 1- and 10-m bead stan-
dards, followed by microscopic examination. In selected
experiments, unfixed large oncosomes were sorted using
size gates with 1- and 10-m bead standards and used
for biological experiments.
Gelatin Zymography and in Vitro Degradation
Assay
Lysed particles isolated from growth media were ana-
lyzed by gelatin zymography (substrate gel electropho-
resis).23 The gelatin degradation assay was performedby seeding isolated particles (1 to 5 g) on FITC-labeled
gelatin-coated coverslips for 1.5 hours, at 37°C, using a
modification of a published protocol.24
Migration Assays
Mouse dermal endothelial cells (MDECs; 1  105), tumor
endothelial cells (TECs), or DU145 cells treated with ves-
icles shed from cells (10 g/mL) were stained with Cell-
Tracker RED CMPTX (Invitrogen), and assayed in Trans-
well FluoroBlok inserts for 16 hours. Cell migration was
measured as previously described.25 Alternatively,
WPMY-1 cells (1.5  105) were seeded into the bottom of
24-well plates and treated for 24 hours with 10 g/mL
LNCaP/MyrAkt1 vesicles. DU145 cells (1  105), labeled
with CellTracker, were seeded into FluoroBlok inserts
placed into the WPMY-1–conditioned media and migra-
tion monitored, as previously described. Vesicles were
unfixed when used in migration assays. Results represent
fold changes from the average of biological triplicates
performed in technical duplicate.
Flow Cytometry
Purified vesicles were stained with propidium iodide (PI)
staining buffer (BD Bioscience, San Jose, CA) or with the
indicated antibodies, processed on a Moflo High-Speed
Cell Sorter (Beckman-Coulter, Brea, CA), and analyzed
using FlowJo software (Treestar, Ashland, OR). Bead
standards, 1 and 10 m (Spherotech, Lake Forest, IL),
were used to set size gates. At least 3000 events were
recorded.26 The following antibodies were used: HA-
probe (F-7) FITC (Santa Cruz Biotechnology), at a dilution
of 1:200, and Cav-1 (N-20) (Santa Cruz Biotechnology),
at a dilution of 1:200.
Electron Microscopy
Large Oncosomes
Purified material was adsorbed to glow-discharged,
carbon-coated copper grids and stained with 0.75%
(w/v) uranyl formate, as previously described.27 Images
were collected on a Philips CM10 electron microscope
(FEI, Hillsboro, OR) operated at an acceleration voltage
of 100 kV. Images were recorded on a 1K charge-cou-
pled device camera (Gatan, Pleasanton, CA) at a mag-
nification of 50,000 and a defocus of approximately
1.5 m.
Human Xenografts
Sections from the paraffin-embedded s.c. tumors were
deparaffinized and fixed for 2 hours in Karnovsky fixative
before post-fixation with 1% OsO4 and 0.03 g/4 mL of
potassium ferrocyanide. Sections were then stained over-
night with 2% uranyl acetate, dehydrated, and embed-
ded overnight with a 1:1 mixture of LX 112 resin and
100% ethanol (Ladd Research, Williston, VT). Electron
micrographs were collected on a JEOL 1400 TEM oper-
ated at an acceleration voltage of 120 kV.
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Sections from the paraffin-embedded mice tumors, hu-
man core biopsy specimens, and human TMA were
stained18,19,28 with the following antibodies: Akt mAb
(Cell Signaling) at a dilution of 1:500; HA.11 mAb, clone
16B12 (Covance), at a dilution of 1:100; and CK18 rabbit
polyclonal Ab (Epitomics, Burlingame, CA), at dilution of
6.5% 
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Patients and Samples
Three human tissue cohorts were used: i) core biopsy
specimens with localized prostate cancer from 15 pa-
tients from the Department of Pathology, University of
Naples, Naples, Italy; ii) a TMA from Ulm, Germany, con-
taining 26 multifocal specimens, with at least two distinct
cancer foci in the prostate gland and one lymph node
metastasis; and iii) a TMA containing 36 benign prostate
samples, 36 organ-confined tumors, and 36 metastatic
tumors, of which 11, 20, and 23 samples, respectively,
were available for the analysis.19,29–31 Informed consent
was obtained from all subjects.
Statistical Analysis
Comparisons between experimental groups were per-
formed using a two-tailed, unpaired, Student’s t-test. A
Pearson’s 2 test was used to assess the correlation
between percentage of MyrAkt1-positive events and tu-
mor weight. A Fisher’s exact test was applied to assess
the association between the presence of large onco-
some-like structures and Gleason score groups and me-
tastases. In all experiments, P  0.05 was considered
significant.
Results
Tumor cells that exhibited the amoeboid feature of mem-
brane blebbing could release large, plasma membrane–
derived vesicles into the extracellular space11 (Figure 1,
A and B, and Figure 2A). To determine whether these
vesicles could be isolated and analyzed, we purified
shed vesicles from the conditioned medium of LNCaP
human prostate cancer cells stably expressing the potent
oncogene MyrAkt118 and from WPMY-1 prostate stromal
cells. The contents of the purified vesicles reacted with PI
Figure 1. Characterization and detection of shed tumor cell–derived vesicles. A:
Prostate cancer (PC3 andDU145), bladder cancer (253J), and glioblastoma (U87) cell
lines are stainedwith CTxB and imagedby confocalmicroscopy. Scale bar 10m.
Arrowhead denotes a large vesicle released in the extracellular space. B: CTxB-
labeled DU145 cells showing large, bulbous membrane protrusions and several
large vesicles released into the surrounding environment. Arrowhead points to a
large membrane bleb resulting in a released vesicle. C: Nucleic acid extracted from
vesicles shed from LNCaP/MyrAkt1 cells. Total RNA/DNA is treatedwith RNase A or
DNase 1 and samples electrophoresed through 2% agarose (D). E: FACS analysis of
vesicles, isolated from the medium of WPMY-1 and LNCaP/MyrAkt1 cells treated
with epidermal growth factor (50 ng/mL), fixed, permeabilized, and stained with PI.
The dot plots depict forward scatter signal (FSC) and FL2 (PI). The red gates
surround PI-positive events, graphed on the right. P  2.2e-16. F: Left panel,
photomicrograph of FITC-labeled gelatin matrix loaded with a biochemical prepa-
rationof vesicles shed fromLNCaP/MyrAkt1 cells, showing large zones of proteolytic
clearance. Original magnification, 40. Trypsin is used as a positive control; a
general protease inhibitor and vehicle serve as negative controls.Right panel, shed
vesicles (SVs) are analyzed via gelatin zymography (substrate gel electrophoresis),
showing active MMP9 and MMP2. G: Top panel, LNCaP/MyrAkt1 cells are stained
with FITC-CTxB. Two membrane vesicles are large. Bottom panel, FITC-labeled
gelatin after exposure to SVs. The CTxB-labeled membrane blebs (n 150;G) and
gelatin degradation spots (n  135; H) are measured by AxioVision version 4.5
(Zeiss) and plotted graphically (mode, 3.1 to 4 m).d
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org), consistent with the presence of RNA (Figure 1C).
This allowed us to detect a PI-positive vesicle population
by FACS. The stromal cells produced substantially fewer
vesicles than the LNCaP/MyrAkt1 cells (P  0.001) (Fig-
ure 1D). Thus, biochemical purification, coupled with
FACS, was in agreement with results using a visual quan-
titative bleb formation assay.11 Shed vesicles from
LNCaP/MyrAkt1 cells produced zones of proteolytic
clearance in a fluorescent gelatin matrix assay24 (Figure
1E) in a similar size range (2 to 4 m) and modal distri-
bution to 1-m-diameter membrane blebs observed
microscopically (Figure 1, F and G). Matrix metalloprotei-
nase (MMP) zymography showed that the vesicle prep-
arations contained bioactive MMP9 and MMP2, two key
proteases involved in tumor cell invasion (Figure 1E).
Shed vesicles isolated from LNCaP/MyrAkt1 cells con-
tained abundant, membrane-localized MyrAkt1, as dem-
onstrated by FACS and immunofluorescence staining
(Figure 2A) and by Western blot analysis (Figure 2B).
These results indicated that MyrAkt1 is a potentially use-
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Sustained ARF6 activation has enhanced tumor cell
invasion in cell and animal model systems,32,33 and ves-
icle shedding may be a potential mechanism for ARF6-
induced acquisition of invasive potential.17 Interrogation
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nificantly, ARF6 ranked in the top 10 percentile of over-
expressed genes in these data sets, and ARF6 mRNA
was significantly up-regulated in metastases and in re-
current disease.
The MMP activity seen with large vesicles shed from
LNCaP/MyrAkt1 cells (Figure 1, F–H) indicated that
they were bioactive. In separate bioactivity tests, these
vesicle preparations stimulated migration of mouse
TECs, MDECs39 (Figure 2C), and DU145 cells (Figure
2D). LNCaP/MyrAkt1 vesicles also activated WPMY-1
stromal cells to produce factors that stimulated migra-
tion of DU145 cells (Figure 2E). LNCaP/MyrAkt1 vesi-
cles also activated Akt1 in WPMY-1 stromal cells (Fig-
ure 2F). Finally, incubation of mouse prostatic
fibroblastic cells with LNCaP/MyrAkt1 vesicles resulted
in increased expression of prometastatic factors:
brain-derived neurotrophic factor, CXCL12, and osteo-
pontin40–42 (Figure 2G). Collectively, these data indi-
cated that LNCaP/MyrAkt1 cells shed oncosomes, in-
cluding particles considerably larger than nanosized
microvesicles, with the potential to contribute to onco-
genic signaling by acting as paracrine effectors of
intertumor cell, tumor-endothelial cell, and epithelial-
stromal reaction.
Large Oncosomes in the Circulation and in Situ
To distinguish large oncosomes from smaller TMV un-
equivocally, we used ultracentrifugation and immuno–
flow cytometry in combination with sizing beads to gen-
erate a calibrated domain of analysis based on size. After
biochemical purification, shed vesicles were stained with
DAPI to verify the absence of cellular contamination (see
Supplemental Figure S2A at http://ajp.amjpathol.org) and
subsequently labeled with an HA antibody for detection
of membrane-localized MyrAkt1.18 MyrAkt1-negative and
MyrAkt1-positive populations were then distinguished on
a cell sorter, with gates set using 1- and 10-m beads
(Figure 3A; see also Supplemental Figure S2B at http://
ajp.amjpathol.org). Because aggregates might poten-
tially be a significant component of the vesicle prepa-
ration, we excluded them from the analysis. To do this,
a forward scatter signal was plotted against pulse
width (PW) of the same signal on a linear scale (Figure
3A). Electronic signal pulses were composed of
pulse height and PW, and the latter was a function of
the time necessary to traverse the laser beam, which
was shorter for single particles. Electric pulses from a
flow cytometer detector with a narrow PW identified a
singlet (bottom), whereas those with a broader PW
identified doublets or possibly clumps (top). To restrict
our analysis to single vesicles, we delineated a region
in which only single events were analyzed based on
their smaller and more homogeneous PW signals and
their corresponding forward scatter signals26 (Figure
3A). Only these events were gated and considered for
further analysis (Figure 3A). Electric pulses generated
from aggregates, as indicated by increased PW (Fig-
ure 3A), were excluded from the analysis,26 as vali-
dated microscopically (Figure 3, A and B). Sorted sin-gle events (1 and 1 m) were visualized by both
fluorescence and electron microscopy, indicating that
large, single vesicles could be distinguished within a
mixed population. Microscopic analysis of retrieved
vesicles after ultracentrifugation and other sorting pro-
cedures indicated that they were not aggregates of
smaller particles and that they had a definable struc-
ture (Figure 3, A and B). These results indicated that
large vesicles could be isolated as discrete events
using a tumor cell–specific marker.
After having demonstrated that membrane blebs shed
by cells could be sorted by FACS as discrete large ves-
icles, we attempted to use a similar approach to isolate
and quantify these blebs in the circulation of mice with
severe combined immunodeficiency carrying LNCaP/
MyrAkt1 xenograft tumors. All mice injected s.c. with ei-
ther LNCaP/MyrAkt1 or LNCaP/LacZ control cells in
Matrigel developed tumors; however, LNCaP/MyrAkt1 tu-
mors were significantly larger than LNCaP/LacZ tumors
(Figure 4A; see also Supplemental Figure S3A at http://
ajp.amjpathol.org). Akt1 was membrane localized in
LNCaP/MyrAkt1 tumors, as detected with both Akt1 and
HA antibodies (Figure 4B; see also Supplemental Figure
S3C at http://ajp.amjpathol.org), confirming in vitro find-
ings.18 The HA antibody was highly specific and did not
recognize antigens in LNCaP/LacZ tumors (see Supple-
mental Figure S3C at http://ajp.amjpathol.org). Plasma
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Figure 3. Analysis of shed vesicles and detection of large oncosomes by
FACS and microscopy. A: Purified vesicles are derived from LNCaP/
MyrAkt1 cells, stained with an FITC-conjugated HA antibody, and plotted
by setting a forward scatter signal (FSC) versus a PW signal on a linear
scale (left panel). Right panels, a schematic representation of two signal
pulses from the flow cytometer detector, corresponding to single particles
(bottom panel) and doublet particles (top panel). Gated single events
(within the red dotted line on the left panel) are visualized at the
microscope and considered for further analysis. Signal pulses generated
from aggregates (outside of the red dotted line) are excluded. B: Fluo-
rescence and electron micrographs of MyrAkt1-positive particles sorted
using size beads 1 and 1 m. Arrowhead, lipid bilayer structure of
the vesicle-encapsulating membrane.
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MyrAkt1-positive events in the 1- to 10-m range that
were sorted with the HA antibody (Figure 4, C and D). The
number of MyrAkt1 events detected by FACS correlated
with tumor weight (P 0.01) (Figure 4E). Because the HA
antibody did not recognize an endogenous epitope in the
mouse,18 these data indicated that tumor-derived large
vesicles from the s.c. xenografts gained access to the
circulation.
Strikingly, MyrAkt1-positive vesicles isolated from the
blood of mice with MyrAkt1 tumors stimulated migration
of normal endothelial cells (Figure 4F), suggesting the
capability of oncosomes in the circulation to evoke pro-
gression-related changes in the microvasculature. A sim-
ilar result was obtained with MyrAkt1-positive vesicles
sorted by FACS in the 1- to 10-m range from the me-
dium of LNCaP/MyrAkt1 cells (Figure 4F), indicating that
large oncosomes were bioactive.
High-magnification microscopy of LNCaP/MyrAkt1 tu-
mors revealed membrane vesicles within a similar size
range to the large oncosomes identified in vitro and in the
circulation of the same animals (Figure 4G). To our knowl-
edge, this type of membrane vesicle has not been pre-
viously described in paraffin sections of prostate tumors.
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10 m 1 m FSC Large oncosome-like structures were evident when sec-tions of LNCaP/MyrAkt1 tumors were stained with H&E
and immunostained with Akt1 and HA antibodies (Figure
4G; see also Supplemental Figure S3D at http://ajp.
amjpathol.org). Morphological features with the appear-
ance of intravasating amoeboid cells were identifiable
by immunostaining with Akt1 antibody (Figure 4G). Akt1-
positive vesicles in tumor tissues were also positive for
ARF6 (see Supplemental Figure S3D at http://ajp.
amjpathol.org), thus resembling large oncosomes se-
creted from LNCaP/MyrAkt1 and DU145 cells (Figure
2B), and in accordance with the amoeboid character of
these cell lines.11 Transmission electron microscopy of
LNCaP/MyrAkt1 tumor sections showed that the tumor
cells produced large, bulbous structures with the appear-
ance of membrane sacs,43 often in the proximity of
vascular lacunae (Figure 4H; see also Supplemental
Figure S3E at http://ajp.amjpathol.org). A higher mag-
nification revealed internal structures with features re-
sembling polyribosomes (see Supplemental Figure
S3F at http://ajp.amjpathol.org). These results sug-
gested that MyrAkt1-positive vesicles detected in the
circulation of tumor-bearing mice arose from mem-
brane blebs similar or identical to amoeboid blebs
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Figure 4. Identification of large oncosomes in
vivo. A: Tumor growth and tumor take in LNCaP/
MyrAkt1 and LNCaP/LacZ xenografts (growth,
P  0.01; s.c. sites free of tumor, P  0.01). B:
Akt1 immunostaining of paraffin sections of the
indicated xenografts. There is prominent Akt
membrane staining in the MyrAkt1 tumors, in
contrast to its diffuse cytosolic staining in the
LacZ tumor sections. C: Left panel, FACS anal-
ysis of 1- to 10-m MyrAkt1-positive vesicles
purified from the plasma of mice carrying
LNCaP/MyrAkt1 and LNCaP/LacZ xenografts.
Dot plot, forward scatter signal (FSC) and FL1
(MyrAkt1); red gate, positive events. D: Quanti-
tative evaluation of MyrAkt1-positive events. A
cutoff corresponding to the 99th percentile of
vesicles isolated from the plasma of mice with
LNCaP/LacZ tumors is chosen to segregate neg-
ative and positive events. E: In mice with LNCaP/
MyrAkt1 tumors, the percentage of MyrAkt1-pos-
itive vesicles correlates with tumor weight. *P 
0.007. F: MDECs exhibit increased migration
when exposed to oncosomes compared with ve-
hicle. Left panel, the vesicles are isolated from
the plasma of mice with MyrAkt1 tumors. Right
panel, the vesicles are derived from the medium
of LNCaP/MyrAkt1 cells. Ctrl, control; SV, shed
vesicle. G: Tumor sections of LNCaP/
MyrAkt1 xenografts are stained with H&E.
Arrowheads, large vesicles, similar in appear-
ance to large oncosomes. Sections are also im-
munostained with an Akt1 antibody, which iden-
tifies Akt1 at the plasma membrane and allows
visualization of large vesicles. H: Tumor sections
of LNCaP/MyrAkt1 xenografts are imaged by
transmission electron microscopy. Membrane
blebs protruding from tumor cells near blood
vessels are highlighted.Akt1 
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Metastatic Prostate Cancer
Next, we investigated whether similar large vesicles
could be identified in human prostate cancer specimens.
ARF6 staining revealed vesicular structures in the 1- to
10-m range. We initially examined a small cohort of
human core biopsy specimens (n  15) with localized
prostate cancer, and identified ARF6-positive large
oncosome-like structures in the tumor tissue of three
specimens (see Supplemental Figure S4A at http://
ajp.amjpathol.org). Significantly, similar vesicular struc-
tures were also identified using a CK18 antibody, which
detected prostate luminal epithelial cells (Figure 5A). To
determine whether the identification of ARF6-positive
vesicles in tissues might reflect clinical status, we exam-
ined a TMA44 containing 120 punches from foci of
localized and metastatic human prostate cancer. High
magnification revealed ARF6-positive vesicles more fre-
quently in foci with a Gleason score 7 compared with
foci with a lower Gleason score (P  0.02), suggesting
that identification of large oncosome-like structures in situ
might indicate tumor progression (see Supplemental Fig-
ure S4B at http://ajp.amjpathol.org). Notably, metastatic
foci exhibited significantly more vesicles (P  0.001)
(Figure 5B). These characteristics represented a previ-
ously unrecognized histological feature of aggressive
prostate cancer.
To determine whether the presence of vesicular struc-
tures identified using similar criteria could differentiate
indolent versus fatal cancer, we used two models of
Pten-deficient mice with a greatly different biological
course. PtenPbKO/Trp53PBKO mice developed prostate
adenocarcinoma that remained organ confined within 10
to 16 weeks after gestation. In comparison, PtenPbKO/
KRAS mice developed distant metastases in the liver and
lung, and they also developed castrate resistance after
androgen ablation.21,22 ARF6-positive vesicles, similar in
appearance and size to those seen in the LNCaP/
MyrAkt1 tumors, were abundant in PtenPbKO/KRAS tis-
sues but were absent in the PtenPbKO/Trp53PbKO prostatic
tissues (see Supplemental Figure S4C at http://ajp.
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Gleasoamjpathol.org). These findings suggested that large on-cosome features in prostate tumors might generally re-
port aggressive disease.
We interrogated an additional human prostate TMA
containing benign samples, organ-confined tumors, and
metastatic tumors.19,28,29 Figure 5C shows representa-
tive images of the absence and presence of large onco-
some-like structures detected using anti-ARF6. These
features were present in 30% of the tumors and were
not detected in benign prostate tissue. We observed a
significant correlation between the presence of large on-
cosome-like features and metastasis (P  0.0008). The
presence of these features also discriminated between
benign and tumor tissue (P  0.0001) (Figure 5D).
Large Oncosomes Containing Cav-1 Identify
Aggressive Prostate Cancer
To determine whether large oncosomes could be identi-
fied using an endogenous tumor progression marker, we
attempted to sort large shed vesicles using Cav-1, a
validated prostate cancer biomarker found in the circu-
lation of patients with advanced disease.45 Cav-1 was
present in membrane vesicles produced by DU145 cells,
suggesting that large shed vesicles were a mobile vehi-
cle for circulating Cav-1 (Figure 2B).11 Cav-1–null LNCaP
cells stably expressing Cav-1–green fluorescent protein
(GFP) produced membrane vesicles that were shed
and contained the fluorescent GFP fusion protein (see
Supplemental Figure S5, A–C, at http://ajp.amjpathol.
org). Enforced expression of Cav-1 in LNCaP cells
significantly increased the rate of membrane blebbing
and shedding (see Supplemental Figure S5D at http://
ajp.amjpathol.org), suggesting that Cav-1 might play an
active role in vesiculation. The ability to sort Cav-1–
GFP–positive particles by FACS (data not shown) in the
1- to 10-m range was validated with a Cav-1–Cy3
antibody, which decorated large oncosome-like GFP-
positive vesicles (see Supplemental Figure S6A at
http://ajp.amjpathol.org). By using the same approach,
we detected endogenous Cav-1 in shed vesicle prep-
arations from DU145 cells (see Supplemental Figure
Absent 
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PCa Mets 
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Figure 5. Large oncosome-like vesicles in meta-
static prostate cancer. A: Representative paraffin sec-
tion of human core biopsy specimens of patientswith
prostate cancer (Gleason score, 4  3) are immuno-
stainedwith CK18 antibody.Arrowheads, structures
resembling large oncosomes. B:Quantitative analysis
of the distribution of ARF6-positive large oncosome-
like vesicles among the diagnostic categories, show-
ing vesicles are significantly more abundant in those
with a Gleason score of 7 than a Gleason score of
7 (P  0.020) and in metastases (Mets) than in
organ-confined tumors [prostate cancer (PCa)] (P 
0.001). C: Representative sections of an additional
prostate cancer TMA stained with ARF6, showing the
absence (left panel) and presence (right panel) of
large oncosome-like vesicles (arrowheads). D: The
presence of structures resembling large oncosomes
significantly discriminates betweennormal and tumor
samples (P  0.0001) and between organ-confined
disease and metastasis (P  0.0008).P
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large oncosomes.
We next attempted to sort Cav-1–positive vesicles
from the plasma of transgenic mice with autochthonous
prostate tumors (TRAMP). TRAMP prostate tissues ex-
pressed high levels of intratumoral Cav-1.28,46 Age-
matched, non-transgenic littermates were used as con-
trols. We again focused our analysis on vesicles with a
1- to 10-m diameter. As a validation method, Cav-1–
positive vesicles (2 to 3 m) detected in plasma were
sorted by FACS and visualized by direct optical imaging
(see Supplemental Figure S7 at http://ajp.amjpathol.org).
Vesicles meeting these criteria were detected in
plasma from TRAMP mice with prostate cancer, but
levels were negligible in plasma of non-transgenic an-
imals and of TRAMP animals with prostate intraepithe-
lial neoplasia (Figure 6A), as confirmed by Western blot
analysis (Figure 6B). These vesicles were substantially
more abundant in the circulation of TRAMP mice with
lymph node and lung metastases (P  0.03) (Figure 6, A
and C; see also Supplemental Figure S8 at http://ajp.am-
jpathol.org). These results suggested that large onco-
somes containing Cav-1 reached the circulation of mice
with prostate cancer, and their presence could reflect the
extent of disease progression. Notably, the presence of
Cav-1–positive vesicles 1 m, which were also de-
tected in the plasma, was not correlated with disease
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E C D progression in this model (Figure 6D). Significantly, largeoncosome-like vesicles recognized using ARF6 staining
were also identified in situ in metastatic TRAMP tumors
(Figure 6E), whereas they were not detected in organ-
confined tumors or in benign tissue.
Discussion
This study describes a type of bioactive membrane ves-
icle previously unrecognized in vivo, which can originate
from amoeboid tumor cells. This class of microvesicle is
large (approximately 1- to 10-m diameter) compared
with other types of bioactive vesicles (1 m), in partic-
ular the substantially smaller exosome-sized vesicles47
(30 to 100 nm; see Supplemental Figure S9 at http://
ajp.amjpathol.org). Consequently, we propose the term
large oncosome as a descriptor. Whether biological and
structural differences exist between these vesicles and
other TMVs remains to be determined.
We show that prostate cancer cell–derived onco-
somes exhibited proteolytic activity on gelatin, and con-
tained bioactive MMP9 and MMP2, suggesting that they
could be a means to focally concentrate proteases that
facilitate migration of tumor cells, thus promoting metas-
tasis. Accordingly, large oncosome-enriched prepara-
tions stimulated migration of DU145 cells, and the result
was accentuated using medium conditioned by stromal
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Figure 6. Large oncosome-like structures con-
taining Cav-1 identify aggressive prostate cancer.
A: FACS analysis of 1- to 10-m Cav-1–positive
vesicles are purified from the plasma of TRAMP
(n  15) and non-transgenic littermates (WT)
(n 10), plotted in a forward scatter signal (FSC)
histogram, and analyzed with respect to the di-
agnostic categories. Mets, metastases; PCa, pros-
tate cancer; PIN, prostate intraepithelial neopla-
sia. B: Large oncosome-like structures, isolated
from the plasma of TRAMP and WT mice, are
analyzed by Western blot analysis. C: The abun-
dance of Cav-1–positive large oncosome-like
structures (1 to 10 m) is significantly increased
in tumor-bearing mice than in controls (P 
0.0007), and dramatically correlates with disease
progression (almost 30-fold difference between
mice with organ-confined tumors and mice with
lung metastases) (P  0.0002). D: The abun-
dance of Cav-1–positive events 1 m does not
reflect changes across the diagnostic categories.
E: Representative paraffin section of a TRAMP
metastatic tumor is stained with ARF6 antibody.
Arrowheads, large oncosome-like structures.Bcells exposed to oncosome material. Oncosomes and
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phenomena, such as intravasation and extravasation, tu-
mor dormancy, and preparation of distant sites before
implantation of metastatic cells, as supported by several
lines of functional evidence.48 In support of this conclu-
sion, our results show that large oncosome preparations
stimulate migration of mouse TECs and, to a lesser ex-
tent, MDECs,39 suggesting that these TMVs might disrupt
the integrity of endothelial cell junctions and thereby in-
crease blood vessel permeability in vivo. The fact that
TECs exhibit a greater migratory response than normal
endothelial cells suggests a putative mechanism under-
lying the greater permeability of tumor blood vessels.
Oncosomes shed from tumor cells may condition the
microenvironment in a manner that favors the production
of soluble factors from stromal cells.49 Through degrada-
tion of the ECM, they could release endothelial permea-
bilization factors that facilitate intravasation.50 Onco-
somes may also induce epigenetic changes and
reprogram endothelial cells by transferring RNA, as has
been hypothesized for other types of microvesicles.48
Because oncosomes can also induce migration of normal
endothelial cells, circulating tumor-derived oncosomes
might promote endothelial leakage, allowing extravasa-
tion and colonization of distant sites (Figure 7).
Our study describes several independent approaches
for the detection of large oncosomes in the circulation
and in formalin-fixed, paraffin-embedded (FFPE) sections
from mouse models and human tumors. Unlike smaller
particles, we show that large oncosome-like structures
are visible in tissues using conventional methods, includ-
ing detection with a clinical biomarker (CK18; Figure 4D)
in FFPE tissue sections, suggesting that a method for
detecting these pathological features could be adapted
for routine histopathological analysis. We also show thatlarge oncosomes can be quantified in platelet-poor
plasma. In several prostate cancer models, and in human
TMAs and core biopsy specimens, large oncosome-like
structures are a feature associated with high Gleason
grade and metastatic disease. Our findings, particularly
those using the LNCaP/MyrAkt1 model, in which the on-
cosomes can be followed from the point of secretion in
tissues to circulation in the blood stream in vivo, support
the conclusion that large oncosomes are produced by
aggressive tumor cells and gain access to the circulation.
In the present study, we focused on prostate cancer
models. However, because similar processes occur in
other solid tumors, we believe it is likely that similar par-
ticles may be detected in other malignancies using com-
parable approaches. Our analysis of the features of these
large TMVs by microscopy indicates that they have an
intrinsic structure, suggesting that they may be stable,
possibly for long periods.
By using specific markers and an FACS method that
allowed sorting of vesicles (1- to 10-m diameter) and
exclusion of aggregates, our results show a correlation
between the abundance of large oncosomes in the
plasma and tumor weight, in mice carrying LNCaP/
MyrAkt1 xenograft tumors. In tissues, we detected large
vesicles by direct inspection of H&E-stained tumor sec-
tions. ARF6 immunostaining facilitated the detection of
similar structures in paraffin-embedded tissue, including
in PtenPbKO/KRAS metastatic prostate tumors, whereas
they were not observed in organ-confined PtenPbKO tu-
mors. More important, PtenPbKO/KRAS mice develop re-
sistance to androgen ablation, suggesting that quantifi-
cation of large oncosome-like features might facilitate
assessment of tumor aggressiveness at initial presenta-
tion or disease progression during therapy. In TRAMP
Figure 7. Model of potential sites of oncosome
bioactivity. Our results suggest a working model
in which oncosomes modify the microenviron-
ment by inducing stromal reaction, ECM degra-
dation, and migration of endothelial cells.
Through these processes, circulating tumor-de-
rived particles may promote endothelial leakage,
allowing extravasation and colonization of dis-
tant sites. LO, large oncosome.animals, the abundance of Cav-1–positive circulating
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with the presence of metastatic tumors, and similar ve-
sicular structures were observed in paraffin sections only
from advanced tumors (Figure 6). Notably, the number of
smaller events (1 m) in the circulation of TRAMP mice
did not correlate with disease progression.
Our findings using independent cohorts of human
prostate cancer tissues demonstrate that the large onco-
some features discriminate between tumor and benign
tissue, including benign prostatic hyperplasia, and also
between organ-confined and metastatic tumors. Identify-
ing predictive criteria for prostate tumor progression has
been extremely problematic, and current paradigms, in-
cluding prostate-specific antigen levels, Gleason score,
and clinical stage, are inadequate as predictive tools. In
particular, serum prostate-specific antigen can be ele-
vated in benign conditions, such as inflammation and
benign prostatic hyperplasia. Collectively, these obser-
vations indicate that assessment of large oncosome fea-
tures in tumor sections or in the circulation might inform
clinical evaluation. The identification of proteins other
than Cav-1 and ARF6 in oncosomes, and discrete RNA
species, might result in additional biomarker tools appli-
cable to clinical medicine. Cav-1 is expressed by normal
endothelial cells and has been identified as a constituent
of circulating nanovesicles.29 For this reason, it is possi-
ble that gating particle size 1 m when Cav-1 is used
as a sorting marker will provide information about disease
course that collection of a smaller TMV may not.
Quantitation of circulating tumor cells (CTCs) is being
evaluated to assess the risk of disease progression for
prostate and other types of cancer. However, the clinical
significance of CTCs remains to be established because
of their extremely small number in peripheral blood com-
pared with the number of blood cells.51 We have dem-
onstrated that large oncosome-like structures can be
separated from plasma in a manner that does not require
the capture of CTCs or other cells. The molecular char-
acterization of large oncosomes may potentially offer a
more sensitive and specific liquid biopsy than CTCs for
patient selection, monitoring of treatment efficacy, and
assessment of drug resistance.
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